Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan (J-HomeCARE II)
Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan
研究概览
详细说明
The new BIOTRONIK ICD family Lumax 540 is capable of measuring the intrathoracic impedance on a daily basis and transmission of impedance trend data via the Home Monitoring technology. In future, this will allow for automatic early detection of imminent decompensation at a presymptomatic stage and immediate initialization of clinical meaningful therapeutic interventions preventing heart failure related hospitalizations. The aim of this investigation is to record long-term impedance trends in heart failure patients with and without HF related events (hospitalizations due to acute decompensation) in order to develop algorithms for device-based early detection and warning of HF deterioration accompanied by pulmonary congestion.
Lumax is the name of a family of implantable ICDs. The primary objective of the therapy is the prevention of sudden cardiac death. The aim is to automatically detect and terminate cardiac arrest caused by ventricular tachyarrhythmia. All major therapeutical approaches from the field of cardiology and electrophysiology are contained within the Lumax family.
Furthermore, the device is capable of treating bradycardia arrhythmias and congestive heart failure. Congestive heart failure is treated with cardiac resynchronization therapy with multisite ventricular pacing known as cardiac resynchronization therapy (CRT).
The integrated Home Monitoring component can provide information about occurring rhythm disturbances and delivered therapies close to real time as well as by intracardiac electrogram (IEGM) Online HD®. Furthermore, statistical data about the patient's condition as well as information about the integrity status of the implant itself are sent.
The implantation of an ICD is a symptomatic therapy with the following objectives:
Termination of spontaneous ventricular fibrillation (VF) through shock delivery Termination of spontaneous ventricular tachycardia (VT) by means of antitachycardia pacing (ATP); in case of ineffective ATP or hemodynamically not tolerated VT with shock delivery Cardiac resynchronization by multisite ventricular pacing (triple-chamber implant) Compensation of bradycardia through ventricular (single-chamber implant) or atrioventricular sequential pacing (dual- and triple-chamber implant)
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Hiroshima、日本
- Hiroshima Shimin Hospital
-
Tokyo、日本
- Tokyo Women's Medical University
-
-
Fukuoka
-
Kitakyushu、Fukuoka、日本、802-8555
- Kokura Kinen Hospital
-
-
Mie
-
Ise、Mie、日本、516-0805
- Yamada Red Cross Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patient eligible for 1-, 2- or 3-chamber ICD implantation according to current guidelines or patient already implanted with a Lumax 540 device or successor
- New York Heart Association (NYHA)-class II to IV
- Left ventricular ejection fraction (LVEF) lower or equal to 35%
- Patient accepts Home Monitoring concept and has sufficient Global System for Mobile Communications (GSM) /General Packet Radio Service (GPRS) net coverage
- Increased risk for HF-related hospitalization according to pre-defined criteria
- Patient information
- Informed consent
Exclusion Criteria:
- Age < 18 years
- Contraindication for ICD implantation
- Post heart transplant (HTX) or actively listed for HTX
- Cardiac surgery within the previous 3 months or planned at time of inclusion
- Acute coronary syndrome within the previous 3 months
- Chronic renal dialysis
- Pregnant or breast-feeding women
- Limited contractual capability
- Participation in another study
- Anticipated non-compliance with the follow-up scheme
- Life expectancy not longer than 1.5 years due to a non-cardiac disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
HF Events
大体时间:21 months follow-up
|
Long-term impedance trends in patients with clinically relevant HF events, to support the development of impedance based detection algorithms.
A posterior assessment of sensitivity and false alarm rate of the detection algorithms.
|
21 months follow-up
|
合作者和调查者
调查人员
- 首席研究员:Shoda Morio, DR、Tokyo Women's University Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.